---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-044783"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:02:24.695309+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma FY2024 net loss $43.3M; cash $69.8M funds operations into 2027

## Summary
- Net loss of $43.3M in FY2024 vs $29.5M in FY2023; R&D expenses rose $3.5M to $20.9M driven by alvelestat and setrusumab.
- Cash and equivalents of $69.8M as of Dec 31, 2024; expected to fund operations into 2027.
- Phase 3 Orbit study of setrusumab in OI progressing; second interim analysis expected mid-2025, final Q4 2025.
- Alvelestat granted EU Orphan Designation for AATD-LD in Q1 2025; partnering discussions ongoing.
- Pre-commercial activities for setrusumab in Europe advancing with NICE and GBA scientific advice.

## SEC filing metadata
- accession: 0000950170-25-044783
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000095017025044783/0000950170-25-044783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000095017025044783/mreo-20250326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-044783
- JSON: https://secwatch.observer/filing/0000950170-25-044783.json
- Plain text: https://secwatch.observer/filing/0000950170-25-044783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.